Back to Search
Start Over
June 2014 Phoenix pulmonary journal club: new therapies for IPF and EBUS for sardoidosis
- Source :
- Southwest Journal of Pulmonary and Critical Care, Vol 8, Iss 6, Pp 340-342 (2014)
- Publication Year :
- 2014
- Publisher :
- Arizona Thoracic Society, 2014.
-
Abstract
- No abstract available. Article truncated at 150 words. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82. Nintedanib is a tyrosine kinase inhibitor that has been shown to decrease the decline of FVC in phase 2 trials of idiopathic pulmonary fibrosis (IPF). This study was a phase 3 trial in which 2 replicate trials comparing nintedanib 150 mg twice daily to placebo. The trials were randomized double blind placebo controlled performed over 205 sites in 24 countries. Inclusion criteria were an age > 40, FVC > 50% and DLCO 30-79%. Patients were excluded if on prednisone > 15 mg/day or any other ...
Details
- Language :
- English
- ISSN :
- 21606773
- Volume :
- 8
- Issue :
- 6
- Database :
- Directory of Open Access Journals
- Journal :
- Southwest Journal of Pulmonary and Critical Care
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1d14cf8a45924e588a8c79bbf7614036
- Document Type :
- article
- Full Text :
- https://doi.org/10.13175/swjpcc078-14